FDA modifies dosing recommendations for Erythropoiesis-Stimulating Agents

Posted by Food and Drug Administration--Press Releases on Friday Jun 24, 2011 Under News

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

Be Sociable, Share!

Comments are closed.